ArticleTranslational psychiatry2016
Serum metabolite profile associates with the development of metabolic co-morbidities in first-episode psychosis.
Article in Translational psychiatry, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 40 citations in OpenAlex.
- Searching for biomarkers in schizophrenia and psychosis: Case-control study using capillary electrophoresis and liquid chromatography time-of-flight mass spectrometry and systematic review for biofluid metabolites.Neuropsychopharmacology reports · 2022Pooled it
- The Pathobiological Underpinnings of Psychosis: From the Stress-Related Hypothesis to a Multisystemic Approach.NeuroSci · 2025Review
- Dysregulation of Serum Exosomal Lipid Metabolism in Schizophrenia: A Biomarker Perspective.Molecular neurobiology · 2025Article
- Metabolomics, Lipidomics, and Antipsychotics: A Systematic Review.Biomedicines · 2023Review
- Metabolomics and Self-Reported Depression, Anxiety, and Phobic Symptoms in the VA Normative Aging Study.Metabolites · 2023Article
- Serum Metabolic Profile in Schizophrenia Patients With Antipsychotic-Induced Constipation and Its relationship With Gut Microbiome.Schizophrenia bulletin · 2023Article
- Metabolomic signatures associated with weight gain and psychosis spectrum diagnoses: A pilot study.Frontiers in psychiatry · 2023Article
- Glucose and Lipid Profiles Predict Anthropometric Changes in Drug-Naïve Adolescents Starting Treatment with Risperidone or Sertraline: A Pilot Study.Biomedicines · 2022Article
- Metabolomic alteration induced by psychotropic drugs: Short-term metabolite profile as a predictor of weight gain evolution.Clinical and translational science · 2021Observational
- Shorter Chain Triglycerides Are Negatively Associated with Symptom Improvement in Schizophrenia.Biomolecules · 2021Article
- Association Between Circulating Lipids and Future Weight Gain in Individuals With an At-Risk Mental State and in First-Episode Psychosis.Schizophrenia bulletin · 2021Article
- Potential Transdiagnostic Lipid Mediators of Inflammatory Activity in Individuals With Serious Mental Illness.Frontiers in psychiatry · 2021Article
- Metabolomic profiles associated with a mouse model of antipsychotic-induced food intake and weight gain.Scientific reports · 2020Article
- Links between central CB1-receptor availability and peripheral endocannabinoids in patients with first episode psychosis.NPJ schizophrenia · 2020Article
- Profiling of lipidomics before and after antipsychotic treatment in first-episode psychosis.European archives of psychiatry and clinical neuroscience · 2020Article
- Targeted Clinical Metabolite Profiling Platform for the Stratification of Diabetic Patients.Metabolites · 2019Article
- Characterizing acyl-carnitine biosignatures for schizophrenia: a longitudinal pre- and post-treatment study.Translational psychiatry · 2019Article
- Metabolomics Biomarkers for Precision Psychiatry.Advances in experimental medicine and biology · 2019Review
- Atypical Antipsychotics and the Human Skeletal Muscle Lipidome.Metabolites · 2018Article
- Atypical Antipsychotic Exposure May Not Differentiate Metabolic Phenotypes of Patients with Schizophrenia.Pharmacotherapy · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 6 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Psychotic patients are at high risk for developing obesity, metabolic syndrome and type 2 diabetes. These metabolic co-morbidities are hypothesized to be related to both treatment side effects as well as to metabolic changes occurring during the psychosis. Earlier metabolomics studies have shown that blood metabolite levels are predictive of insulin resistance and type 2 diabetes in the general population as well as sensitive to the effects of antipsychotics. In this study, we aimed to identify the metabolite profiles predicting future weight gain and other metabolic abnormalities in psychotic patients. We applied comprehensive metabolomics to investigate serum metabolite profiles in a prospective study setting in 36 first-episode psychosis patients during the first year of the antipsychotic treatment and 19 controls. While corroborating several earlier findings when comparing cases and controls and the effects of the antipsychotic medication, we also found that prospective weight gain in psychotic patients was associated with increased levels of triacylglycerols with low carbon number and double-bond count at baseline, that is, lipids known to be associated with increased liver fat. Our study suggests that metabolite profiles may be used to identify the psychotic patients most vulnerable to develop metabolic co-morbidities, and may point to a pharmacological approach to counteract the antipsychotic-induced weight gain.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.